WilmerHale Advises Casdin Capital in $150M Series B Financing with MOMA Therapeutics
On May 10, 2022, MOMA Therapeutics, a biopharmaceutical company discovering the next generation of precision medicines targeting the molecular machines that underlie human disease,
announced the completion of a $150 million Series B financing. The financing was led by Goldman Sachs Asset Management, with participation from other new investors Section 32, Pavilion Capital, Invus and LifeSci Venture Partners. All of MOMA’s Series A investors, including Third Rock Ventures, Nextech Invest, Cormorant Asset Management, Casdin Capital, Rock Springs Capital, Creacion Ventures, Alexandria Venture Investments and other undisclosed investors, also participated in the round.
The WilmerHale team advising Casdin Capital was led by
Eric Hanson and included
Nare Aleksanyan.
